KMKonstantin V. Menshikov

Konstantin V. Menshikov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Konstantin V. Menshikov has a total of 467 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • De-escalation of neoadjuvant chemotherapy in resectable oral squamous cell carcinoma: results of a comparative analysis of DC and DCF modes

    by S. I. Musin, K. V. Menshikov, A. V. Sultanbaev, I. A. Sharifgaleev, T. R. Baimuratov, N. A. Sharafutdinova, M. R. Shafikova, E. V. Tiulcov, S. V. Vtorushin, E. L. Choynzonov

    Introduction. The three-drug regimen consisting of docetaxel, cisplatin, and 5-fluorouracil (DCF) has traditionally been regarded as one of the most active neoadjuvant chemotherapy regimens for locally advanced head and neck squamous cell carcinoma. However, its use is associated with a high incidence of treatment-related adverse events. Therefore, the two-drug regimen of docetaxel plus cisplatin (DC) may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma. Aim. To compare the short-term antitumor efficacy and toxicity profile of two- versus three-drug taxane-platinum neoadjuvant chemotherapy regimens in patients with resectable locally advanced oral squamous cell carcinoma. Materials and methods. This single-center retrospective cohort study included 45 patients with resectable locally advanced oral squamous cell carcinoma who received neoadjuvant chemotherapy followed by surgery between 2020 and 2026. Twenty-eight patients (62.2 %) received the DCF regimen, whereas 17 (37.8 %) received the DC regimen. Radiological response was assessed according to Response Evaluation Criteria in Solid Tumors 1.1. Pathologic response was classified as pathologic complete response, major pathologic response, or unfavorable pathologic response. Treatment-related toxicity was evaluated using the Common Terminology Criteria for Adverse Events, version 5.0. All patients received primary prophylaxis against chemotherapy-induced neutropenia with epegfilgrastim. Results. The objective response rate was 58.8 % in the DC group and 53.6 % in the DCF group (p = 0.767), whereas disease control rates were 100 and 89.3 %, respectively (p = 0.279). Tumor downstaging (reduction in T category) was observed in 64.7 and 64.3 % of patients, respectively (p = 1.000), while nodal downstaging (reduction in N category) occurred in 17.6 and 21.4 %, respectively (p = 1.000). The complete pathologic response rate was 11.8 % in the DC group and 10.7 % in the DCF group (p = 0.990), whereas the favorable pathologic response rate (complete pathologic response + major pathologic response) was 41.2 and 39.3 %, respectively (p = 1.000). R0 resection was achieved in all patients. Grade 3 adverse events occurred more frequently in the DCF group than in the DC group (53.6 % vs 17.6 %, p = 0.028), primarily because of a higher incidence of grade 3 non-hematological toxicity (42.9 % vs 5.9 %, p = 0.015). No cases of febrile neutropenia were observed. Conclusion. Among patients with resectable locally advanced oral squamous cell carcinoma, no statistically significant differences were observed between the DC and DCF regimens regarding objective response, disease control, tumor and nodal downstaging, pathologic response, or R0 resection rates. The DC regimen was associated with a significantly lower incidence of grade 3 adverse events, primarily owing to reduced non-hematological toxicity. These findings suggest that DC may represent a potential treatment de-escalation strategy for patients with initially resectable oral squamous cell carcinoma.

  • Open Access

    Efficacy of pembrolizumab plus lenvatinib versus alternative drug regimens in patients with recurrent endometrial cancer after platinum based chemotherapy: a retrospective cohort study

    by Летучих Ангелина Николаевна, Angelina N. Letuchikh, Румянцев А. А., A. А. Rumyantsev, Исраелян Э. Р., E. R. Israelyan, Абляметова А. С., A. S. Ablyametova, A. V. Trusova, Трусова А. В., et al.

    Introduction. The combination of pembrolizumab and lenvatinib is the preferred second-line treatment for patients with recurrent endometrial cancer (EC) with proficient mismatch repair (pMMR) after platinum-based chemotherapy (CT). However, in real-world clinical practice, this option may be unavailable for some patients. Objective. To evaluate the efficacy of pembrolizumab plus lenvatinib compared with alternative СT regimens in patients with recurrent EC with pMMR tumor status upon progression after platinum based CT. Materials and Methods. A multicenter retrospective cohort study was conducted, including treatment data from patients with advanced and recurrent EC with рMMR tumor status from 37 oncology centers in Russia between December 2020 and December 2025. Patients were assigned to two groups according to the therapy received: immuno-targeted therapy (ITT) consisting of pembrolizumab plus lenvatinib, and alternative CT regimens, which included either platinum-based CT reinduction or non-platinum-based CT. To minimize the impact of baseline characteristic differences between the groups, patients were matched using cardinality matching (matching with maximization of the balanced sample size) at a 1:1 ratio. Group balancing was performed for the following variables: age, histological subtype, stage IV disease, receipt of radical/palliative surgery as first-line treatment, and platinum-free interval (PFI). The standardized mean difference was within ≤0.1 in absolute value for all variables. The primary endpoint was progression-free survival (PFS). Results. A total of 173 patients were enrolled in the study, of whom 106 constituted the ITT group and 67 constituted the CT group. From the initial study population, after cardinality matching, two groups of 67 patients each were formed. The median age was 60 (range, 36–80) years in the ITT group and 61 (range, 37–79) years in the alternative CT group; primary surgery was performed in 61/67 (91%) and 62/67 (93%) of patients, respectively. The median PFI was 6.9 (range, 0.0–106.5) months in the pembrolizumab–lenvatinib combination group and 9.1 (range, 0.0–69.0) months in the control group. At a median follow-up of 36.1 months (95% CI, 31.8–42.6), the median PFS in the ITT group was 9.9 months (95% CI, 7.2–12.9) versus 6.8 months (95% CI, 4.7–8.3) in the alternative CT group, which was statistically significant (HR 0.58; 95% CI, 0.40–0.85; p = 0.005). Conclusions. Treatment with the combination of pembrolizumab and lenvatinib is associated with longer PFS compared with alternative CT regimens in the matched cohort of patients with recurrent and advanced EC with MSS/pMMR tumor status upon progression after platinum-based CT.

  • Open Access

    Hepatocellular carcinoma: a clinical case of durable response to atezolizumab and bevacizumab combination therapy

    by K. V. Menshikov, Sh. I. Musin, N. I. Sultanbaeva, I. A. Menshikova, A. V. Sultanbaev, Sh. N. Galimov, V. A. Turtsov, A. A. Izmailov, К. В. Меньшиков, Ш. И. Мусин, et al.

    Hepatocellular carcinoma (HCC) is the seventh most common cancer in the world and the second leading cause of cancerrelated death. This clinical observation demonstrates the effectiveness of first-line combination therapy with atezolizumab (PDL1 inhibitor) and bevacizumab (VEGFR inhibitor) in a patient with unresectable HCC, which is particularly relevant in light of the growing demand for new treatments for this aggressive tumor. The patient was diagnosed with HCC stage IVA TNM and stage C BCLC at the age of 44, with multiple liver lesions and portal vein thrombosis. After 44 months of therapy, the patient’s disease was under control, with stable normalization of AFP levels, and follow-up CT scans showed partial response with a reduction in the size of the tumor conglomerates. The treatment was associated with minimal side effects, primarily hypothyroidism and hyperthyroidism. The results of HCC treatment with atezolizumab plus bevacizumab indicated that the long-term administration of this combination significantly improved overall survival in patients. Thus, this clinical case demonstrated the potential efficacy of atezolizumab and bevacizumab combination as a first-line therapy in difficult patients with generalized neoplastic processes, which is of great importance for practical oncology.

  • Open Access

    Intracranial activity characteristics of third-generation ALK inhibitor

    by A. F. Nasretdinov, A. V. Sultanbaev, K. V. Menshikov, V. E. Askarov, Sh. I. Musin, A. A. Izmailov, А. Ф. Насретдинов, А. В. Султанбаев, К. B. Меньшиков, В. Е. Аскаров, et al.

    Introduction. Intracranial involvement in ALK-positive non-small cell lung cancer is associated with poor prognosis and resistance to certain therapies due to the blood-brain barrier. Third-generation tyrosine kinase inhibitors, particularly lorlatinib, demonstrate high efficacy due to their lipophilicity and low affinity for P-glycoprotein. Aim. To present a clinical case of successful use of lorlatinib for controlling intracranial progression in a patient with ALKpositive non-small cell lung cancer after developing resistance to alectinib, as well as to analyze the factors contributing to the antitumor response in the central nervous system. Mat erials and methods. We describe a case of a female patient born in 1963 diagnosed with stage IVB peripheral lung adenocarcinoma (T1cN3M1c, oss, cer), ALK-positive. After disease progression on alectinib therapy (development of multiple brain metastases), lorlatinib was prescribed at a dose of 100 mg per day, followed by dose reduction to 75 mg per day. Efficacy was assessed using brain MRI and chest CT. R e s u l t s and di sc u ssi on. While receiving lorlatinib, the patient achieved a complete intracranial response, confirmed by MRI at 3, 6, 9, and 12 months of follow-up. The duration of central nervous system tumor growth control after switching therapy was 12 months or more. Adverse events (grade 1 hypercholesterolemia, grade 2 peripheral neuropathy and edema) were managed by dose reduction to 75 mg per day without loss of efficacy. Overall lorlatinib showed high intracranial and an expected toxicity Conclusion. Lorlatinib is a highly effective agent for overcoming intracranial resistance in patients with ALK-positive lung cancer who progress on alectinib. This case supports the use of lorlatinib in the second-line setting for isolated central nervous system progression, potentially avoiding radiotherapy and its associated complications.

  • Video-Endoscopic Hemithyroidectomy via the Unilateral Axillo-Breast Approach (UABA): Results of a Single-Center Retrospective Study

    by Shamil Musin, Timerlan Baimuratov, Vasily Ilyin, Sergei Osokin, Natalya Sharafutdinova, Margarita Shafikova, Konstantin Menshikov, Alexander Sultanbaev, Marat Zamilov, Maxim Vakhitov, et al.

  • Open Access

    Effectiveness and safety of regional anesthesia techniques as an adjunct to general anesthesia in thyroidectomy: a systematic review

    by Dmitry A. Zaitсev, Shamil I. Musin, Askhat I. Karimov, Adel A. Izmailov, Sergei V. Osokin, Konstantin V. Menshikov, Alexander V. Sultanbayev, Natalia A. Sharafutdinova, Timerlan R. Baimuratov, Eduard R. Fatkulin, et al.

    Thyroidectomy is associated with moderate or intense postoperative pain and a high incidence of postoperative nausea and vomiting, along with a high need for analgesic (both opioid and non-opioid). Despite the widespread use of regional techniques (particularly cervical plexus blocks), their comparative effectiveness and safety remain insufficiently systematized; moreover, data on minimally invasive and robot-assisted approaches are limited. A systematic review was conducted in accordance with the recommendations of PRISMA-2020. The review protocol was not registered. The search was conducted in PubMed, EMBASE, ScienceDirect, Google Scholar, and eLibrary for the period from 2015 to 2025. Inclusion criteria were: randomized controlled trials, prospective and retrospective cohort studies comparing general anesthesia in combination with regional techniques (cervical plexus block, infiltration anesthesia in the surgical wound area) with a control group in adult patients undergoing elective thyroidectomy. Twenty studies were selected for qualitative synthesis. Qualitative analysis of the data demonstrated significant advantages of using combined anesthesia methods. The use of regional blocks (especially ultrasound-guided superficial cervical plexus block) in addition to general anesthesia can significantly reduce the intensity of postoperative pain during the first 24 hours; reduce the need for opioid analgesics by 1.5–3 times; reduce the frequency of postoperative nausea and vomiting by 40%–80%; and show a tendency to shorten recovery time in the ICU. The frequency of specific complications of regional methods was low ( 5%), and in some cases transient. The available data suggest that the addition of regional techniques to general anesthesia may reduce the intensity of postoperative pain, the need for opioids, and the frequency of post-thyroidectomy nausea and vomiting. However, interpretation of the results is limited by the clinical and methodological heterogeneity of the included studies, as well as the risk of bias.

  • Open Access

    Biopsy of the sentinel lymph nodes in early oral cancer: literature review

    by S. V. Osokin, Sh. I. Musin, N. A. Sharafutdinova, K. V. Menshikov, V. V. Ilyin, T. R. Baymuratov, M. R. Shafikova

    Biopsy of the sentinel lymph nodes is a modern technique of surgical staging of head and neck tumors. It allows to determine advisability of cervical lymph node dissection in patients with early-stage oral cancer. The article presents a literature review on the history, methodology, and clinical efficacy of sentinel lymph node biopsy. It is shown that technological development and implementation of new indicators increase method efficacy, minimizing unnecessary surgical interventions and decreasing the risk of complications.

  • Open Access

    Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in BRAF metastatic melanoma: updated 4-year OS analyses

    by I. V. Samoylenko, Yu. M. Kolontareva, E. V. Kogay, N. V. Zhukova, I. A. Utyashev, M. E. Ivannikov, K. V. Menshikov, M. V. Zinkevich, K. V. Orlova, Yu. V. Vakhabova, et al.

    Introduction . Combined immune-targeted therapy is a new registered approach for treating metastatic melanoma. Identifying subgroups of patients who may benefit more from simultaneous rather than sequential administration of triple combination drugs is of current scientific interest to the medical community. Aim . To present a 4-year updated analysis of the efficacy and safety of triple therapy with atezolizumab + vemurafenib + cobimetinib (AVC) in patients with BRAF-mutated advanced melanoma in real-world clinical practice in Russia. Materials and methods . A prospective non-interventional study included 59 patients with metastatic BRAF+ melanoma receiving the triple combination of vemurafenib, cobimetinib, atezolizumab. The primary endpoint was 24-month OS. Additionally, PFS, ORR, and risk factors influencing OS were evaluated. This paper is a 4-year update of a previously published analysis. Results . The median OS in the entire population was 23.67 months (95% CI 13.19–NR), and the median PFS in the entire population was 14.97 months (95% CI 8.00–24.39). An objective response was recorded in 57.6% of patients. Cox multivariate analysis revealed a significant impact of age, presence of lung metastases, and large tumor mass (10–15 cm vs ≤6 cm) on OS. The presence of liver metastases reduced median survival by more than 2.5 times, but no significant effect was proven. BMI, ECOG ≥ 2, CNS metastases, line of therapy, and PD-L1 did not have a statistically significant effect. Conclusion . Triple therapy demonstrates high clinical efficacy in patients with metastatic BRAF+ melanoma in real-world clinical practice in the analyzed population of patients with an unfavorable prognosis – CNS involvement, liver involvement, and second-line and subsequent therapy. Age, the presence of lung metastases, and tumor size were found to be prognostic factors affecting survival.

  • Open Access

    Cholangiocarcinoma: A clinical case of long-lasting response to immunochemotherapy

    by K. V. Menshikov, Sh. I. Musin, N. I. Sultanbaeva, A. A. Volkov, I. A. Menshikova, A. F. Nasretdinov, A. F. Aymatova, A. V. Sultanbaev, I. A. Tuzankina

    Cholangiocellular carcinoma is a heterogeneous group of malignant neoplasms of the biliary tract. It accounts for approximately 3% of all gastrointestinal tumors and is the second most common primary liver tumor after hepatocellular carcinoma. Surgery is the only cure. Surgical treatments are among the most complex in hepatopancreatobiliary surgery. Standard first-line therapy with gemcitabine-based chemotherapy has demonstrated a modest improvement in survival in patients with advanced cholangiocellular carcinoma. Despite its role as the cornerstone of first-line therapy, chemotherapy produces suboptimal response rates, and overall survival highlights the urgent need for improved therapeutic strategies. The TOPAZ-1 trial, which included an immuno-oncology agent, demonstrated an improvement in overall survival. In the case described above, the patient first presented for this condition in 2022. After diagnosis verification, chemoembolization and surgical treatment were performed. Disease progression began in 2023. Based on the progression, chemotherapy in combination with durvalumab was initiated. In the case of local progression, a course of stereotactic radiotherapy was administered. This clinical case demonstrates the results of combining systemic therapy and local control methods. Progression-free survival with durvalumab therapy was 26 months. Thus, this option demonstrated the potential of modern immunochemotherapy and stereotactic radiotherapy.

  • Open Access

    REACT: Real-world survival outcomes with atezolizumab, bevacizumab, and chemotherapy for treatment of advanced non-squamous NSCLC

    by D. I. Yudin, K. K. Laktionov, R. A. Zukov, I. L. Obraz, D. V. Perunov, M. M. Magamedova, F. V. Moiseenko, E. О. Elsakova, A. V. Sultanbaev, K. V. Menshikov, et al.

    Introduction . Atezolizumab, bevacizumab, and chemotherapy (ABCP) is a standard of care for advanced non-squamous NSCLC, including post-TKI patients with EGFR/ALK mutations. Real-world data on ABCP efficacy in Russia are limited. Aim . To evaluate OS and PFS in real-world NSCLC patients who received ≥4 cycles of first-line ABCP followed by atezolizumab-bevacizumab (AB) maintenance. Materials and methods . REACT is an observational, retrospective, multicenter study of adult patients with advanced NSCLC (diagnosed 2021–2023) who received ≥4 ABCP cycles and started AB maintenance. Key endpoints included ORR, PFS, and OS. Results . Data from 108 patients were included: 78 patients (72.2%) received ABCP in first line (wild type) and 30 (27.8%) were post-TKI (EGFR/ALK+). Median age 57.6 years; 63.9% male. Baseline metastases: CNS (17.6%), liver (8.3%), bone (33.3%). ORR was 56.5% (59.0% first line); DCR 98.2%. Median PFS was 14.7 months (95% CI 12.4–23.9) in first line group and 9.3 months (95% CI 7.4–14.6) in post-TKI group. Median OS was 34.4 months (95% CI 21.8–NR) in first line group and 24.2 months (95% CI 21.8–NR) post-TKI. 2-year OS rates were 52.7% and 54.4%, respectively. High tumor burden (≥3 sites), large sum of longest diameters, and bone metastases were negative prognostic factors. Age, sex, smoking, and PD-L1 status had no significant impact. Conclusion . In this cohort, the ABCP regimen was highly effective. Results align with IMpower150 trial for post-TKI patients and demonstrate prolonged survival in the first-line setting.